# A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Study · id `cardio:ct-nct07754461` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07754461](<https://clinicaltrials.gov/study/NCT07754461>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07754461

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

## Technical summary

Registry record NCT07754461. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-24 (actual); primary completion 2028-01-17 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT07754461, source copy `cardio:ctgov-nct07754461-2026-11-13`, retrieved 2026-11-18)
- Started: 2026-08-24 (actual) (ClinicalTrials.gov record NCT07754461, source copy `cardio:ctgov-nct07754461-2026-11-13`, retrieved 2026-11-18)
- Primary completion: 2028-01-17 (anticipated) (ClinicalTrials.gov record NCT07754461, source copy `cardio:ctgov-nct07754461-2026-11-13`, retrieved 2026-11-18)
- Completion: 2028-05-01 (anticipated) (ClinicalTrials.gov record NCT07754461, source copy `cardio:ctgov-nct07754461-2026-11-13`, retrieved 2026-11-18)
- Countries: United States; Australia; Canada; India; New Zealand; Puerto Rico (ClinicalTrials.gov record NCT07754461, source copy `cardio:ctgov-nct07754461-2026-11-13`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07754461-2026-11-13`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
- Condition: Type 2 Diabetes
- Intervention (Drug): Placebo
- Intervention (Drug): Survodutide
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: 250a49d6277052e2e41f298cd9b3a09209914cffff2efa5a0e64524cf705a999
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
